Core Insights - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is recognized as a promising AI stock, particularly in the context of drug discovery, despite facing pressure after Nvidia divested its entire stake in the company [1][2]. Group 1: Company Overview - Recursion Pharmaceuticals is a "TechBio" company that employs artificial intelligence, machine learning, and high-throughput automation to enhance drug discovery processes, aiming to lower the high failure rates and costs associated with traditional drug development [4]. - The company operates a proprietary AI-powered platform known as the Recursion Operating System, which integrates clinical data to support patient translation [4][3]. Group 2: Recent Developments - Nvidia previously held 7.71 million shares in Recursion Pharmaceuticals for two years, which was seen as a sign of confidence in the company's AI-driven drug discovery approach [2]. - On February 18, Recursion announced plans to share business updates and report Q4 and full-year 2025 results on February 25 [3]. - Last year, Recursion unveiled a whole-genome map consisting of 46 million images of microglial cells to aid in the identification of new drug targets [3].